Outcomes in Refractory Aggressive Diffuse Large B Cell Lymphoma (DLBCL): Results from the International SCHOLAR-1 Study

Although patients with relapsed/refractory DLBCL have heterogeneous outcomes to subsequent therapy, patients with chemorefractory disease (r-DLBCL) have a worse prognosis. SCHOLAR-1 is a patient-level meta-analysis designed to assess outcomes in r-DLBCL.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Michael Crump, Sattva Neelapu, Umar Farooq, Eric Van Den Neste, John Kuruvilla, Mohamed Ahmed, Brian Link, Annette Hay, James Cerhan, Liting Zhu, Sami Boussetta, Lei Feng, Matthew Maurer, Lynn Navale, Jeffrey Wiezorek, William Go, Christian Gisselbrecht Source Type: research